Rankings
▼
Calendar
ANIP Q4 2025 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
ANIP
ANI Pharmaceuticals, Inc.
$2B
Q4 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$247M
+29.6% YoY
Gross Profit
$238M
96.2% margin
Operating Income
$48M
19.5% margin
Net Income
$27M
11.1% margin
EPS (Diluted)
$1.17
QoQ Revenue Growth
+8.4%
Cash Flow
Operating Cash Flow
$30M
Free Cash Flow
$7M
Stock-Based Comp.
$10M
Balance Sheet
Total Assets
$1.4B
Total Liabilities
$900M
Stockholders' Equity
$541M
Cash & Equivalents
$286M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$247M
$191M
+29.6%
Gross Profit
$238M
$110M
+115.4%
Operating Income
$48M
-$4M
+1200.4%
Net Income
$27M
-$10M
+367.5%
Revenue Segments
Sales of rare disease pharmaceutical products
$131M
53%
Total Sales of Generics and Other
$103M
42%
Sales of Established Brands
$12M
5%
← FY 2025
All Quarters